Dr. Stella Lee
ENT (Otolaryngology) (Otolaryngology Physician)
1400 Locust St, Mercy, Building D, Suite 2100
Pittsburgh, PA 15219
- Medicare participating
At a glance
- Medical school
- R Franklin University of Med & Sci/Chicago Medical School (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 232
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: R Franklin University of Med & Sci/Chicago Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Otolaryngology Physician primary
PA license MD442225
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
Medical groups
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 232
- Services billed
- 878
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of nasal passages using an endoscope | 227 | 148 |
| Established patient office or other outpatient visit, 20-29 minutes | 96 | 58 |
| Established patient office or other outpatient visit, 30-39 minutes | 61 | 53 |
| New patient office or other outpatient visit, 45-59 minutes | 55 | 55 |
| New patient office or other outpatient visit, 30-44 minutes | 30 | 30 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 17 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mupirocin Other prescribers in Pittsburgh, PA | 132 |
| Fluticasone Propionate Other prescribers in Pittsburgh, PA | 83 |
| Azelastine Hcl Other prescribers in Pittsburgh, PA | 31 |
| Ipratropium Bromide Other prescribers in Pittsburgh, PA | 30 |
| Cefuroxime (cefuroxime axetil) Other prescribers in Pittsburgh, PA | 21 |
| Oxycodone Hcl Other prescribers in Pittsburgh, PA | 20 |
| Mometasone Furoate Other prescribers in Pittsburgh, PA | 17 |
| Budesonide Other prescribers in Pittsburgh, PA | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 68 payments worth $132,209 in total to this clinician.
| Genzyme Corporation | $73,417 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $37,108 |
| GlaxoSmithKline, LLC. | $12,809 |
| Insmed, Inc. | $4,897 |
| Regeneron Pharmaceuticals, Inc. | $3,536 |
| Aerin Medical Inc. | $368 |
| Medtronic, Inc. | $73.72 |
| Compensation for services other than consulting (speaking, faculty) | $59,229 |
|---|---|
| Consulting Fee | $51,741 |
| Travel and Lodging | $20,173 |
| Food and Beverage | $1,066 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Apr 6, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $33,744 |
| Genzyme Corporation Jun 20, 2025 | Consulting Fee DUPIXENT · Immunology | $12,744 |
| AstraZeneca Pharmaceuticals LP May 21, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $5,200 |
| AstraZeneca Pharmaceuticals LP Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $5,200 |
| Genzyme Corporation Mar 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,185 |
| Genzyme Corporation Apr 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind | $4,964 |
| GlaxoSmithKline, LLC. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,800 |
| Insmed, Inc. Apr 4, 2025 | Consulting Fee | $4,458 |
| Genzyme Corporation Jun 21, 2025 | Consulting Fee DUPIXENT · Immunology | $3,800 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $3,600 |
All 52 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,800 |
| GlaxoSmithKline, LLC. Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,400 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Travel and Lodging travel to Oak Creek, WI · in-kind | $1,055 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Travel and Lodging travel to Milwaukee, WI · in-kind | $670 |
| GlaxoSmithKline, LLC. Dec 4, 2025 | Travel and Lodging travel to Oak Creek, WI · in-kind | $283 |
| GlaxoSmithKline, LLC. Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,200 |
| AstraZeneca Pharmaceuticals LP Oct 27, 2025 | Consulting Fee TEZSPIRE · Respiratory Company’s descriptionResearch Related Service | $3,575 |
| AstraZeneca Pharmaceuticals LP Oct 9, 2025 | Consulting Fee TEZSPIRE · Respiratory Company’s descriptionResearch Related Service | $1,625 |
| Genzyme Corporation Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| GlaxoSmithKline, LLC. Sep 15, 2025 | Consulting Fee NUCALA · IMMUNOLOGY | $2,400 |
| AstraZeneca Pharmaceuticals LP Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $5,200 |
| AstraZeneca Pharmaceuticals LP Sep 7, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Palm Beach, FL · in-kind Company’s descriptionSpeaker Expenses | $405 |
| AstraZeneca Pharmaceuticals LP Sep 7, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Palm Beach, FL · in-kind Company’s descriptionSpeaker Expenses | $257 |
| AstraZeneca Pharmaceuticals LP Sep 7, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Palm Beach, FL · in-kind Company’s descriptionSpeaker Expenses | $210 |
| AstraZeneca Pharmaceuticals LP Sep 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $650 |
| AstraZeneca Pharmaceuticals LP Jul 23, 2025 | Consulting Fee TEZSPIRE · Respiratory | $2,925 |
| AstraZeneca Pharmaceuticals LP Jul 10, 2025 | Consulting Fee TEZSPIRE · Respiratory Company’s descriptionResearch Related Service | $2,925 |
| AstraZeneca Pharmaceuticals LP Jul 3, 2025 | Consulting Fee | $3,250 |
| Genzyme Corporation Jun 21, 2025 | Consulting Fee DUPIXENT · Immunology | $3,800 |
| Genzyme Corporation Jun 21, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $3,600 |
| Genzyme Corporation Jun 21, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary | $226 |
| Genzyme Corporation Jun 21, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $196 |
| Genzyme Corporation Jun 21, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $98.69 |
| Genzyme Corporation Jun 20, 2025 | Consulting Fee DUPIXENT · Immunology | $12,744 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $3,600 |
| Genzyme Corporation Jun 20, 2025 | Consulting Fee | $1,728 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $196 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary | $137 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $118 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary | $17.25 |
| AstraZeneca Pharmaceuticals LP May 21, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $5,200 |
| AstraZeneca Pharmaceuticals LP May 17, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to New Orleans, LA · in-kind Company’s descriptionSpeaker Expenses | $1,277 |
| AstraZeneca Pharmaceuticals LP May 17, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to New Orleans, LA · in-kind Company’s descriptionSpeaker Expenses | $983 |
| AstraZeneca Pharmaceuticals LP May 17, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to New Orleans, LA · in-kind Company’s descriptionSpeaker Expenses | $391 |
| Regeneron Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $416 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,080 |
| Regeneron Pharmaceuticals, Inc. Apr 18, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,040 |
| AstraZeneca Pharmaceuticals LP Apr 11, 2025 | Consulting Fee TEZSPIRE · Respiratory Company’s descriptionResearch Related Service | $975 |
| Genzyme Corporation Apr 6, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $33,744 |
| Genzyme Corporation Apr 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind | $4,964 |
| Genzyme Corporation Apr 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind | $501 |
| Genzyme Corporation Apr 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind | $369 |
| Genzyme Corporation Apr 6, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Lisboa, Portugal | $241 |
| Insmed, Inc. Apr 4, 2025 | Consulting Fee | $4,458 |
| Genzyme Corporation Mar 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,185 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Insmed, Inc. Feb 28, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $375 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| AstraZeneca Pharmaceuticals LP Feb 6, 2025 | Consulting Fee TEZSPIRE · Respiratory | $1,950 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Consulting Fee FASENRA · Respiratory | $2,600 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Consulting Fee TEZSPIRE · Respiratory | $2,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $110,909 in research payments for these studies, mostly to the institutions running them.
- A Multicentre Single-Arm Phase 3b Study to Assess Changes in Symptoms in Adult Participants with Chronic Rhinosinusitis with Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE)
AstraZeneca Pharmaceuticals LP - A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
Sanofi US Services Inc. · Completed · NCT06454240 - A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT
AstraZeneca Pharmaceuticals LP - A Multicentre Single-Arm Phase 3b Study to Assess Changes in Symptoms in Adult Participants with Chronic Rhinosinusitis with Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE)
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.